YONGHE
雍禾医疗

Yonghe Medical Group Co., Ltd.
雍禾醫療集團有限公司
(Incorporated in the Cayman Islands with limited liability)
(Stock Code: 2279)

SUPPLEMENTAL ANNOUNCEMENT IN RELATION TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2024

Reference is made to the annual report of Yonghe Medical Group Co., Ltd. (the "**Company**") for the year ended 31 December 2024 published on 29 April 2025 (the "**2024 Annual Report**"). Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the 2024 Annual Report. This announcement provides supplemental information to the 2024 Annual Report and should be read in conjunction with the 2024 Annual Report.

Contractual Arrangements

In addition to the information provided in the 2024 Annual Report, the Company wishes to provide the following additional information in relation to the Contractual Arrangements pursuant to the Rule 14A.71(4) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**").

The Contractual Arrangements apply to the 30% and 10% equity interests in Yonghe Investment and Chengdu Yonghe, respectively. As a result, the Company has obtained control of the VIE Entities through Beijing Haiyouyou and, at the Company's sole discretion, can receive substantially all of the economic interest returns generated by the VIE Entities.

As has been disclosed on pages 63 and 64 in the Annual Report, under the Exclusive Operation Services Agreement, the VIE Entities, Registered Shareholders and Beijing Xunyi agreed to engage Beijing Haiyouyou as their exclusive provider of technical support, consulting services and other services in exchange for a service fee, and such service fee shall be an amount equal to the distributable net profit of the VIE Entities of a given audited financial year, after deducting losses from the previous financial years (if any) and any statutory provident fund (if applicable). Apart from the service fees, Beijing Xunyi and the VIE Entities shall reimburse all reasonable costs, reimbursed payments and out-of-pocket expenses incurred by Beijing Haiyouyou in connection with the performance of the Exclusive Operation Services Agreement and provision of services.

Therefore, the total consideration in relation to the continuing connected transactions contemplated under the Contractual Arrangements shall be deemed as 30% and 10% economic interest returns generated by Yonghe Investment and Chengdu Yonghe respectively. The Company hereby provides the revenue and loss of Yonghe Investment and Chengdu Yonghe for the years ended 31 December 2023 and 2024 respectively in the below for indication purpose:

	For the year ended 31 December 2023		For the year ended 31 December 2024	
	Revenue	**Loss for the year**	**Revenue**	**Loss for the year**
	RMB'000	*RMB'000*	*RMB'000*	*RMB'000*
Yonghe Investment	1,688,904	(463,058)	1,725,940	(167,318)
Chengdu Yonghe	76,771	(4,126)	75,391	(2,616)

Treasury Shares

In addition to the information provided in the 2024 Annual Report, the Company wishes to provide to the following additional information in relation to the Treasury Shares pursuant to the paragraph 10(4) of Appendix D2 of the Listing Rules.

The Company will utilize such Treasury Shares for various purposes as permitted under the Listing Rules, including but not limited to employee share scheme, sale or transfer, subject to market conditions and its capital management needs.

By Order of the Board
Yonghe Medical Group Co., Ltd.
ZHANG Yu
Chairman of the Board

Hong Kong, November 21, 2025

As at the date of this announcement, the executive directors of the Company are Mr. ZHANG Yu, Mr. ZHANG Hui and Ms. HAN Zhimei; the non-executive director of the Company is Mr. GENG Jiaqi; and the independent non-executive directors of the Company are Ms. LIANG Jihong, Mr. CHAN Peng Kuan and Mr. LI Xiaopei.